Lucid Diagnostics (LUCD) News Today $0.79 -0.02 (-2.05%) (As of 05:44 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed PublicationDecember 11, 2024 | prnewswire.comLucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $7.00 at Ascendiant Capital MarketsDecember 10, 2024 | americanbankingnews.comLucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term MilestonesDecember 3, 2024 | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 30.6% in NovemberLucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the recipient of a large decrease in short interest in November. As of November 15th, there was short interest totalling 293,100 shares, a decrease of 30.6% from the October 31st total of 422,400 shares. Based on an average daily volume of 319,300 shares, the short-interest ratio is currently 0.9 days. Approximately 1.5% of the company's stock are sold short.November 29, 2024 | marketbeat.comLucid Diagnostics’ Strategic Financial Maneuvering and AgreementsNovember 29, 2024 | tipranks.comLucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA testNovember 21, 2024 | markets.businessinsider.comLucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA TestNovember 20, 2024 | prnewswire.comLucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNovember 18, 2024 | prnewswire.comLucid Diagnostics: Strong Growth Potential Justifies Buy RatingNovember 15, 2024 | markets.businessinsider.comLucid Diagnostics: Buy Rating Affirmed on Strong Revenue Growth and Future Expansion PotentialNovember 15, 2024 | markets.businessinsider.comLucid Diagnostics (NASDAQ:LUCD) Price Target Cut to $2.00 by Analysts at Cantor FitzgeraldCantor Fitzgerald decreased their target price on Lucid Diagnostics from $3.00 to $2.00 and set an "overweight" rating for the company in a report on Friday.November 15, 2024 | marketbeat.comLucid Diagnostics (NASDAQ:LUCD) Earns "Buy" Rating from Canaccord Genuity GroupCanaccord Genuity Group reaffirmed a "buy" rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday.November 14, 2024 | marketbeat.comLucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ...November 14, 2024 | finance.yahoo.comLucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comNeedham & Company LLC Reiterates Buy Rating for Lucid Diagnostics (NASDAQ:LUCD)Needham & Company LLC reiterated a "buy" rating and issued a $2.50 target price on shares of Lucid Diagnostics in a research note on Thursday.November 14, 2024 | marketbeat.comLucid Diagnostics Reports Revenue Growth and Secures FundingNovember 14, 2024 | markets.businessinsider.comOptimistic Outlook for Lucid Diagnostics: Buy Rating Amid Strong Q3 Performance and Future Growth PotentialNovember 14, 2024 | markets.businessinsider.comLucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comLucid Diagnostics Provides Business Update and Third Quarter 2024 Financial ResultsNovember 13, 2024 | prnewswire.comA Glimpse of Lucid Diagnostics's Earnings PotentialNovember 13, 2024 | benzinga.comLucid Diagnostics (LUCD) Scheduled to Post Quarterly Earnings on WednesdayLucid Diagnostics (NASDAQ:LUCD) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 9, 2024 | marketbeat.comLucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationNovember 7, 2024 | prnewswire.comLucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue DriversNovember 5, 2024 | prnewswire.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024October 30, 2024 | prnewswire.comLucid Diagnostics (NASDAQ:LUCD) Trading 1.5% Higher - Here's What HappenedLucid Diagnostics (NASDAQ:LUCD) Trading 1.5% Higher - Here's WhyOctober 30, 2024 | marketbeat.comLucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA TestOctober 15, 2024 | prnewswire.comLucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 9, 2024 | prnewswire.comLucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024October 8, 2024 | prnewswire.comOctober's 4 Best Penny Stocks: High-Risk, High-Reward Picks (LUCD)Penny stocks are a risky but potentially rewarding opportunity for investors willing to take on their uncertainty; these stocks may stand out from the pack.October 4, 2024 | marketbeat.comLucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL PlayersOctober 1, 2024 | finance.yahoo.comAmerican Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer TestSeptember 24, 2024 | prnewswire.comPAVmed Announces Efforts to Regain Compliance with Nasdaq Listing RequirementsSeptember 16, 2024 | prnewswire.comLucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressSeptember 10, 2024 | prnewswire.comLucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthSeptember 3, 2024 | prnewswire.comLucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and CancerAugust 20, 2024 | prnewswire.comPAVmed Inc.: PAVmed Provides Business Update and Second Quarter 2024 Financial ResultsAugust 14, 2024 | finanznachrichten.deLucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comLucid Diagnostics: Strong Buy Rating on Rising Test Volume and Promising Coverage ProspectsAugust 13, 2024 | markets.businessinsider.comThe American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal CancerAugust 13, 2024 | prnewswire.comLucid Diagnostics Provides Business Update and Second Quarter 2024 Financial ResultsAugust 12, 2024 | finance.yahoo.comLucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing EventAugust 8, 2024 | prnewswire.comLucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer TestingAugust 6, 2024 | prnewswire.comLucid Diagnostics to Participate in Upcoming Investor ConferencesAugust 5, 2024 | prnewswire.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024July 29, 2024 | prnewswire.comLucid Diagnostics Announces Record Quarterly EsoGuard® Test VolumeJuly 23, 2024 | prnewswire.comLucid Diagnostics Launches New Corporate WebsiteJuly 11, 2024 | prnewswire.comLucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening PopulationJuly 2, 2024 | prnewswire.com4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer TestingJune 12, 2024 | prnewswire.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024May 20, 2024 | investorplace.comBuy Rating Affirmed for Lucid Diagnostics Amid Positive Financial and Clinical MilestonesMay 15, 2024 | markets.businessinsider.com Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address Uncover the Top Gold Stock of the Bull Market (Ad)Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play? Click here to see how this opportunity could transform your portfolio. LUCD Media Mentions By Week LUCD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LUCD News Sentiment▼-0.500.48▲Average Medical News Sentiment LUCD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LUCD Articles This Week▼01▲LUCD Articles Average Week Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SGHT News LAKE News PDEX News BWAY News NVRO News SRTS News ZJYL News TLSI News TELA News GUTS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LUCD) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LUCD Stock Alerts